Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Toxicities Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

NCT01719562
View directory record Official record
Conditions
Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
Interventions
Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration
Procedure · Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 6, 2026, 2:17 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

NCT07660666
View directory record Official record
Conditions
Melanoma
Interventions
Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Active, not recruiting Not applicable Interventional

DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer

NCT04766190
View directory record Official record
Conditions
Financial Toxicity, Cancer, Question Prompt List, Breast Cancer, Prostate Cancer
Interventions
Group 2: The DISCO App, Group 1: Usual Care, Group 3: The DISCO App + Booster
Behavioral
Lead sponsor
Lauren Hamel
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

NCT04469075
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
Interventions
Clindamycin Phosphate, Triamcinolone Acetonide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Evanston, Illinois • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

NCT02096588
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Simvastatin, Doxorubicin/cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

NCT00245050
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT00751101
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
Interventions
Nicotine patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Interventions to Decrease Financial Toxicity

NCT05939440
View directory record Official record
Conditions
Cancer, Breast, Cancer Colorectal, Cancer, Ovarian, Cervical Cancer, Uterine Cancer, Vulvar Cancer
Interventions
Proactive Cost of Care (P-COC) intervention, Usual Care
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

NCT02012608
View directory record Official record
Conditions
Breast Cancer
Interventions
Glutamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

NCT00109005
View directory record Official record
Conditions
Melanoma
Interventions
Revlimid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 6, 2026, 2:17 AM EDT
Completed No phase listed Observational

Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides

NCT00001473
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

NCT00668512
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Antimelanoma injection of GSL alpha-Gal
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

NCT05403736
View directory record Official record
Conditions
Cancer
Interventions
Cardiac Aggressive Risk MitigAtion Plan
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

NCT00855309
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir sodium
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting No phase listed Observational

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

NCT06675643
View directory record Official record
Conditions
Malignant Skin Neoplasm, Melanoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933
View directory record Official record
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Early Phase 1 Interventional

AvenovaTM as a Sterile Skin Preparation Agent

NCT02990013
View directory record Official record
Conditions
Cleaning Product Causing Toxic Effect
Interventions
Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

NCT01856543
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Eucerin, Mometasone Furoate 0.1%
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated No phase listed Observational

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504
View directory record Official record
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 14, 2013 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy

NCT02796365
View directory record Official record
Conditions
Doxorubicin Induced Cardiomyopathy, Breast Cancer, Gastric Cancer, Leukemia
Interventions
Exercise
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 6, 2026, 2:17 AM EDT